Rivaroxaban Excels in ‘Real-World’ Trial
ثبت نشده
چکیده
Survivors of acute lung injury are likely to experience depression and physical impairment for up to 2 years after leaving the intensive care unit. In a prospective study, 40% of patients had new-onset depression and 66% had new physical impairment after discharge. The findings seem inextricably linked on both psychological and physiological levels, Dr. Oscar J. Bienvenu and his colleagues wrote in the American Journal of Respiratory and Critical Care Medicine. “Depressive symptoms may decrease motivation for and reward from the physical activities necessary for recovery of maintenance of functioning. ... [They] can also amplify symptoms of general medical illnesses, and an increased physical symptom load could negatively affect functioning.” In addition, there may be less-understood links between depression and physical functioning, wrote Dr. Bienvenu of Late Stage of Sepsis May Hold Treatment Option
منابع مشابه
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke. Vitamin K antagonists, mainly warfarin, have been used for decades to prevent ischemic stroke in AF, but their use is limited due to interactions with food and other drugs, as well as the requirement for regular monitoring of the inte...
متن کاملReal-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
Venous thromboembolism (VTE) is a potential cause of morbidity and mortality in patients after major orthopaedic surgery. Based on the results of the international phase III RECORD (Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) program, the oral, direct Factor Xa inhibitor rivaroxaban has been approved in many countries for the preventi...
متن کاملRivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke, accounting for up to 15% of strokes in the general population. The European Society of Cardiology now recommends direct oral anticoagulants, such as rivaroxaban, apixaban, and dabigatran, in preference to vitamin K antagonist therapy for the pre...
متن کاملRivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. Venous thromboembolism is a very common comorbidity in patients with cancer. Therefore, the aim of this study was to evaluate the effic...
متن کاملRepresentativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
OBJECTIVE Three oral anticoagulants have reported study results for stroke prevention in patients with atrial fibrillation (AF) (dabigatran etexilate, rivaroxaban and apixaban); all demonstrated superiority or non-inferiority compared with warfarin (RE-LY, ARISTOTLE and ROCKET-AF). This study aimed to assess the representativeness for the real-world AF population, particularly the population el...
متن کامل